MX2020001046A - Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. - Google Patents
Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos.Info
- Publication number
- MX2020001046A MX2020001046A MX2020001046A MX2020001046A MX2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A MX 2020001046 A MX2020001046 A MX 2020001046A
- Authority
- MX
- Mexico
- Prior art keywords
- immunogenic composition
- peptide derived
- fusion peptide
- superantigen
- toxoids
- Prior art date
Links
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 title abstract 3
- 231100000617 superantigen Toxicity 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 title 1
- 102000015636 Oligopeptides Human genes 0.000 abstract 1
- 108010038807 Oligopeptides Proteins 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537706P | 2017-07-27 | 2017-07-27 | |
| PCT/US2018/043687 WO2019023341A1 (en) | 2017-07-27 | 2018-07-25 | IMMUNOGENIC COMPOSITION COMPRISING A MELTING PEPTIDE DERIVED FROM TOXOIDS OF SUPERANTIGENES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001046A true MX2020001046A (es) | 2020-08-06 |
Family
ID=65041106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001046A MX2020001046A (es) | 2017-07-27 | 2018-07-25 | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11260120B2 (enExample) |
| EP (1) | EP3658181A4 (enExample) |
| JP (1) | JP7303791B2 (enExample) |
| CN (1) | CN110996993B (enExample) |
| CA (1) | CA3069747A1 (enExample) |
| MX (1) | MX2020001046A (enExample) |
| WO (1) | WO2019023341A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116497003A (zh) * | 2023-06-29 | 2023-07-28 | 北京百普赛斯生物科技股份有限公司 | 一种从溶液中纯化目标蛋白的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6593114B1 (en) | 1996-01-05 | 2003-07-15 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
| TW517061B (en) | 1996-03-29 | 2003-01-11 | Pharmacia & Amp Upjohn Ab | Modified/chimeric superantigens and their use |
| US7087235B2 (en) | 1997-06-25 | 2006-08-08 | The United States Of America As Represented By The Secretary Of The Army | Fusion protein of streptococcal pyrogenic exotoxins |
| US6713284B2 (en) | 1997-06-25 | 2004-03-30 | The United States Of America As Represented By The Secretary Of The Army | Bacterial superantigen vaccines |
| AU758019B2 (en) | 1998-07-10 | 2003-03-13 | U.S. Medical Research Institute Of Infectious Diseases | Anthrax vaccine |
| SE0102327D0 (sv) | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| GB0118155D0 (en) | 2001-07-25 | 2001-09-19 | Lorantis Ltd | Superantigen |
| DK2083016T3 (da) | 2001-11-26 | 2011-10-03 | U S Medical Res Inst Of Infectious Diseases | Bakterielle superantigenvacciner |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| US7754225B2 (en) | 2006-07-20 | 2010-07-13 | Glaxosmithkline Biologicals S.A. | Method of protecting against staphylococcal infection |
| WO2008154101A1 (en) | 2007-06-06 | 2008-12-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Psm peptides as vaccine targets against methicillin-resistant staphylococcus aureus |
| CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| AU2012214677B2 (en) | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| AU2012266880A1 (en) | 2011-03-16 | 2013-10-03 | Regents Of The University Of Minnesota | Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus |
| CA2857666C (en) | 2011-12-02 | 2020-08-11 | Integrated Biotherapeutics, Inc. | Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides |
| US9815872B2 (en) | 2013-06-19 | 2017-11-14 | Integrated Biotherapeutics, Inc. | Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof |
-
2018
- 2018-07-25 CN CN201880047111.4A patent/CN110996993B/zh active Active
- 2018-07-25 JP JP2020503935A patent/JP7303791B2/ja active Active
- 2018-07-25 US US16/633,664 patent/US11260120B2/en active Active
- 2018-07-25 EP EP18838475.4A patent/EP3658181A4/en active Pending
- 2018-07-25 MX MX2020001046A patent/MX2020001046A/es unknown
- 2018-07-25 WO PCT/US2018/043687 patent/WO2019023341A1/en not_active Ceased
- 2018-07-25 CA CA3069747A patent/CA3069747A1/en active Pending
-
2022
- 2022-02-25 US US17/680,897 patent/US11826412B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7303791B2 (ja) | 2023-07-05 |
| WO2019023341A1 (en) | 2019-01-31 |
| EP3658181A4 (en) | 2021-06-16 |
| CN110996993A (zh) | 2020-04-10 |
| US20200206335A1 (en) | 2020-07-02 |
| US11260120B2 (en) | 2022-03-01 |
| US11826412B2 (en) | 2023-11-28 |
| CA3069747A1 (en) | 2019-01-31 |
| CN110996993B (zh) | 2024-05-31 |
| EP3658181A1 (en) | 2020-06-03 |
| JP2020537488A (ja) | 2020-12-24 |
| US20220257744A1 (en) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY40283A (es) | Método para alterar una propiedad de una planta | |
| AU2017263237A1 (en) | GDF15 fusion proteins and uses thereof | |
| AU2018243910A8 (en) | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof | |
| WO2020039359A3 (en) | Escherichia coli compositions and methods thereof | |
| MX2020005170A (es) | Formulaciones de proteinas de fusion vegfr-fc. | |
| WO2020008377A3 (en) | Ionic self-assembling peptides | |
| WO2012085872A3 (en) | Stable immunogenic compositions of staphylococcus aureus antigens | |
| MX2020006328A (es) | Composición inmunogénica. | |
| EA201690859A1 (ru) | Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli | |
| PH12017500450A1 (en) | Flavivirus virus like particle | |
| WO2015031778A3 (en) | Compositions and methods for the treatment or prevention of tuberculosis | |
| MX388814B (es) | Formulaciones de oxido de polialquileno-asparaginasa y metodos de preparacion y uso del mismo. | |
| PE20161406A1 (es) | Proteinas de fusion tatk-cdkl5, composiciones, formulaciones y uso de estas | |
| MX2021002909A (es) | Vacunas de proteinas de fusion neumococicas. | |
| PH12020551618A1 (en) | Erenumab compositions and uses thereof | |
| EA201990451A1 (ru) | Композиция многовалентных пневмококковых конъюгатов капсульного полисахарида с белком-носителем и ее применение | |
| MX2019015007A (es) | Composiciones inmunogénicas que comprenden los polipéptidos derivados de la leucocidina de staphylococcus aureus luka y lukb. | |
| MX2023009921A (es) | Formulaciones de proteinas de fusion ace2-fc. | |
| ZA202202180B (en) | Engineered hcv e2 immunogens and related vaccine compositions | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| MX2017015375A (es) | Variantes de oxintomodulina pegilada. | |
| GB2568440A (en) | Modified factor H binding protein | |
| MX2020001046A (es) | Composicion inmunogenica que comprende un peptido de fusion derivado de toxoides de superantigenos. | |
| MX2022004061A (es) | Peptidos de estafilococo y metodos de uso. | |
| IL270917A (en) | Recombinant ROBO2 proteins, preparations, methods and their use |